VISIONBLUE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for VISIONBLUE (VISIONBLUE).

How it works

Visionblue (trypan blue) is a dye that selectively stains the anterior lens capsule and vitreous, enhancing visualization during ophthalmic surgeries such as cataract extraction and vitrectomy. It does not exert pharmacological activity but acts as a vital stain.

What the body does with it

Metabolism	Visionblue is not metabolized; it is cleared from the eye via aqueous humor outflow and systemic absorption is negligible.
Excretion	Primarily eliminated unchanged via renal glomerular filtration; minimal biliary excretion (<5%).
Half-life	Approximately 2.5 hours in patients with normal renal function; prolonged in renal impairment (up to 12 hours).
Protein binding	Negligible (<5%), primarily to albumin.
Volume of Distribution	0.2 L/kg, reflecting confinement to extracellular fluid and minimal tissue binding.
Bioavailability	Not applicable for systemic routes; intraocular administration yields direct local effect.
Onset of Action	Intraocular administration: immediate staining of anterior lens capsule upon contact.
Duration of Action	Staining persists for 10-15 minutes during cataract surgery; eliminated from the eye within 24 hours.

Classification & Brands

Dosing & administration

0.5 mL of 0.025% solution intracameral injection (single use).

Dosage form	SOLUTION
Renal impairment	No dosage adjustment required; VISIONBLUE is not systemically absorbed.
Liver impairment	No dosage adjustment required; VISIONBLUE is not systemically absorbed.
Pediatric use	Safety and efficacy not established in pediatric patients; no standard dosing available.
Geriatric use	No specific adjustment; use adult dosing as indicated.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for VISIONBLUE (VISIONBLUE).

Breastfeeding	Minimal systemic absorption; M/P ratio not reported. Compatible with breastfeeding but avoid direct infant eye contact.
Teratogenic Risk	No teratogenic effects in animal studies; limited human data. Avoid use in pregnancy unless benefits outweigh risks.
Fetal Monitoring	Standard prenatal care; no specific monitoring required.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["Known hypersensitivity to trypan blue or any component of the formulation","Intraocular use in patients with significant corneal endothelial compromise"]

Clinical Precautions

Precautions

["Intraocular use only; do not inject intravenously","Potential for corneal endothelial toxicity if excessive volume or prolonged contact","May cause transient increase in intraocular pressure","Hypersensitivity reactions have been reported","Use with caution in patients with compromised corneal endothelium"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

VISIONBLUE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for VISIONBLUE (VISIONBLUE).

How it works

What the body does with it

Metabolism	Visionblue is not metabolized; it is cleared from the eye via aqueous humor outflow and systemic absorption is negligible.
Excretion	Primarily eliminated unchanged via renal glomerular filtration; minimal biliary excretion (<5%).
Half-life	Approximately 2.5 hours in patients with normal renal function; prolonged in renal impairment (up to 12 hours).
Protein binding	Negligible (<5%), primarily to albumin.
Volume of Distribution	0.2 L/kg, reflecting confinement to extracellular fluid and minimal tissue binding.
Bioavailability	Not applicable for systemic routes; intraocular administration yields direct local effect.
Onset of Action	Intraocular administration: immediate staining of anterior lens capsule upon contact.
Duration of Action	Staining persists for 10-15 minutes during cataract surgery; eliminated from the eye within 24 hours.

Classification & Brands

Dosing & administration

0.5 mL of 0.025% solution intracameral injection (single use).

Dosage form	SOLUTION
Renal impairment	No dosage adjustment required; VISIONBLUE is not systemically absorbed.
Liver impairment	No dosage adjustment required; VISIONBLUE is not systemically absorbed.
Pediatric use	Safety and efficacy not established in pediatric patients; no standard dosing available.
Geriatric use	No specific adjustment; use adult dosing as indicated.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for VISIONBLUE (VISIONBLUE).

Breastfeeding	Minimal systemic absorption; M/P ratio not reported. Compatible with breastfeeding but avoid direct infant eye contact.
Teratogenic Risk	No teratogenic effects in animal studies; limited human data. Avoid use in pregnancy unless benefits outweigh risks.
Fetal Monitoring	Standard prenatal care; no specific monitoring required.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["Known hypersensitivity to trypan blue or any component of the formulation","Intraocular use in patients with significant corneal endothelial compromise"]